Clearside Biomedical Inc
NASDAQ:CLSD
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.9274
2.02
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Clearside Biomedical Inc
Clearside Biomedical Inc
Cash from Financing Activities
Clearside Biomedical Inc
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Clearside Biomedical Inc
NASDAQ:CLSD
|
Cash from Financing Activities
$14.1m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash from Financing Activities
-$6.4B
|
CAGR 3-Years
27%
|
CAGR 5-Years
21%
|
CAGR 10-Years
5%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash from Financing Activities
$7.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
Pfizer Inc
NYSE:PFE
|
Cash from Financing Activities
-$5.7B
|
CAGR 3-Years
34%
|
CAGR 5-Years
14%
|
CAGR 10-Years
8%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cash from Financing Activities
-$6.3B
|
CAGR 3-Years
-72%
|
CAGR 5-Years
13%
|
CAGR 10-Years
3%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash from Financing Activities
$5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Clearside Biomedical Inc
Glance View
Clearside Biomedical, Inc. is a biopharmaceutical company, which engages in the development of drug therapies to treat blinding diseases of the eye. The company is headquartered in Alpharetta, Georgia and currently employs 34 full-time employees. The company went IPO on 2016-06-02. The firm is focused on developing and delivering therapies to the back of the eye diseases through the suprachoroidal space (SCS). Its SCS injection platform utilizing its SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted delivery of a variety of therapies to the macula, retina or choroid to preserve and improve vision in patients with sight-threatening eye diseases. The company is focused on developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector, and it also partners with companies developing other ophthalmic therapeutics to be administered using its SCS injection platform. Its lead product candidate, XIPERE, is a preservative-free suspension of the corticosteroid triamcinolone acetonide (TA), formulated for administration through suprachoroidal injection. Its pipeline includes CLS-AX, CLS-301 and Gene Therapy.
See Also
What is Clearside Biomedical Inc's Cash from Financing Activities?
Cash from Financing Activities
14.1m
USD
Based on the financial report for Sep 30, 2024, Clearside Biomedical Inc's Cash from Financing Activities amounts to 14.1m USD.
What is Clearside Biomedical Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
6%
Over the last year, the Cash from Financing Activities growth was 1 037%. The average annual Cash from Financing Activities growth rates for Clearside Biomedical Inc have been -23% over the past three years , 6% over the past five years .
You don't have any saved screeners yet
